Eastman Chemical CO EMN
We take great care to ensure that the data presented and summarized in this overview for EASTMAN CHEMICAL CO is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding EMN
View all-
Vanguard Group Inc Valley Forge, PA14.8MShares$1.33 Billion0.02% of portfolio
-
Black Rock Inc. New York, NY8.42MShares$756 Million0.02% of portfolio
-
Capital Research Global Investors Los Angeles, CA5.89MShares$529 Million0.12% of portfolio
-
Franklin Resources Inc San Mateo, CA5.79MShares$520 Million0.15% of portfolio
-
State Street Corp Boston, MA5.23MShares$470 Million0.02% of portfolio
-
Putnam Investments LLC Boston, MA4.36MShares$391 Million0.54% of portfolio
-
Morgan Stanley New York, NY3.85MShares$346 Million0.03% of portfolio
-
Invesco Ltd. Atlanta, GA2.84MShares$256 Million0.05% of portfolio
-
Massachusetts Financial Services CO Boston, MA2.84MShares$256 Million0.09% of portfolio
-
Geode Capital Management, LLC Boston, MA2.83MShares$255 Million0.02% of portfolio
Latest Institutional Activity in EMN
Top Purchases
Top Sells
About EMN
Eastman Chemical Company operates as a specialty materials company in the United States and internationally. The company's Additives & Functional Products segment offers hydrocarbon and rosin resins; organic acid-based solutions; amine derivative-based building blocks; metam-based soil fumigants, thiram and ziram based fungicides, and plant growth regulators; specialty coalescent, specialty and commodity solvents, paint additives, and specialty polymers; heat transfer and aviation fluids; insoluble sulfur and anti-degradant rubber additives; and performance resins. It serves transportation, personal care, wellness, food, feed, agriculture, building and construction, water treatment, energy, consumables, durables, and electronics markets. Its Advanced Materials segment provides copolyesters, cellulosic biopolymers, cellulose esters, polyvinyl butyral (PVB) sheets, and window and protective films, and aftermarket applied film products for value-added end uses in the transportation, durables, electronics, building and construction, medical and pharma, and consumables markets. The company's Chemical Intermediates segment offers methylamines and salts higher amines and solvents; Olefin and acetyl derivatives, ethylene, and commodity solvents; and primary non-phthalate and phthalate plasticizers, and niche non- phthalate plasticizers to the industrial chemicals and processing, building and construction, health and wellness, and agrochemicals. Its Fibers segment provides cellulose acetate tow, triacetin, cellulose acetate flake, acetic acid, and acetic anhydride for use in filtration media primarily cigarette filters; natural and solution dyed acetate yarns for use in consumables, and health and wellness markets; and wet-laid nonwoven media, specialty and engineered papers, and cellulose acetate fibers for transportation, industrial, agriculture and mining, and aerospace markets. Eastman Chemical Company was founded in 1920 and is headquartered in Kingsport, Tennessee.
Insider Transactions at EMN
Insider Transaction List
View allDate | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
Mar 07
2025
|
Brad A Lich EVP & CCO |
SELL
Bona fide gift
|
Direct |
1,750
-2.14%
|
-
|
Mar 03
2025
|
Michelle H Caveness SVP & Chf. Mfg. Ofc. |
SELL
Open market or private sale
|
Direct |
1,147
-49.57%
|
$112,406
$98.51 P/Share
|
Mar 03
2025
|
Michelle H Caveness SVP & Chf. Mfg. Ofc. |
BUY
Exercise of conversion of derivative security
|
Direct |
1,147
+33.14%
|
$95,201
$83.84 P/Share
|
Feb 26
2025
|
Mark J Costa CEO & Board Chair |
SELL
Open market or private sale
|
Direct |
4,834
-1.07%
|
$483,400
$100.08 P/Share
|
Feb 26
2025
|
Mark J Costa CEO & Board Chair |
BUY
Exercise of conversion of derivative security
|
Direct |
4,834
+1.06%
|
$314,210
$65.16 P/Share
|
Feb 21
2025
|
William Thomas Mc Lain Jr. EVP, CFO |
SELL
Open market or private sale
|
Direct |
1,963
-3.79%
|
$198,263
$101.0 P/Share
|
Feb 21
2025
|
William Thomas Mc Lain Jr. EVP, CFO |
BUY
Exercise of conversion of derivative security
|
Direct |
1,963
+3.65%
|
$145,262
$74.46 P/Share
|
Feb 20
2025
|
Adrian James Holt SVP, Chf HR Ofcr |
SELL
Open market or private sale
|
Direct |
2,037
-100.0%
|
$205,737
$101.18 P/Share
|
Feb 18
2025
|
Brian Travis Smith EVP, AFP, Mfg., WWEC & HSE |
SELL
Payment of exercise price or tax liability
|
Direct |
1,233
-7.6%
|
$126,999
$103.47 P/Share
|
Feb 18
2025
|
Brian Travis Smith EVP, AFP, Mfg., WWEC & HSE |
BUY
Grant, award, or other acquisition
|
Direct |
4,193
+20.55%
|
-
|
Feb 18
2025
|
Christopher Moore Killian SVP, CTO & Sust. Ofc, |
SELL
Payment of exercise price or tax liability
|
Direct |
3,210
-13.24%
|
$330,630
$103.47 P/Share
|
Feb 18
2025
|
Christopher Moore Killian SVP, CTO & Sust. Ofc, |
BUY
Grant, award, or other acquisition
|
Direct |
11,767
+32.67%
|
-
|
Feb 18
2025
|
William Thomas Mc Lain Jr. EVP, CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
6,167
-11.01%
|
$635,201
$103.47 P/Share
|
Feb 18
2025
|
William Thomas Mc Lain Jr. EVP, CFO |
BUY
Grant, award, or other acquisition
|
Direct |
19,331
+25.65%
|
-
|
Feb 18
2025
|
Michelle H Caveness SVP & Chf. Mfg. Ofc. |
SELL
Payment of exercise price or tax liability
|
Direct |
440
-27.38%
|
$45,320
$103.47 P/Share
|
Feb 18
2025
|
Michelle H Caveness SVP & Chf. Mfg. Ofc. |
BUY
Grant, award, or other acquisition
|
Direct |
1,607
+50.0%
|
-
|
Feb 18
2025
|
Mark J Costa CEO & Board Chair |
SELL
Payment of exercise price or tax liability
|
Direct |
30,638
-6.42%
|
$3,155,714
$103.47 P/Share
|
Feb 18
2025
|
Mark J Costa CEO & Board Chair |
BUY
Grant, award, or other acquisition
|
Direct |
81,525
+14.59%
|
-
|
Feb 18
2025
|
Adrian James Holt SVP, Chf HR Ofcr |
SELL
Payment of exercise price or tax liability
|
Direct |
697
-25.49%
|
$71,791
$103.47 P/Share
|
Feb 18
2025
|
Adrian James Holt SVP, Chf HR Ofcr |
BUY
Grant, award, or other acquisition
|
Direct |
2,734
+50.0%
|
-
|
Last 12 Months Summary
Grant, award, or other acquisition | 176K shares |
---|---|
Exercise of conversion of derivative security | 313K shares |
Open market or private sale | 330K shares |
---|---|
Payment of exercise price or tax liability | 58.3K shares |
Bona fide gift | 1.75K shares |